We focused on core Alzheimer’s disease biomarkers,3 especially tau in the presence of amyloid, which, to our knowledge, has not been directly studied in relation to CSF Alzheimer’s disease biomarkers and brain volume. The gene discussed is MAPT; the disease is Alzheimer disease.